Search for Clinical Trials

Clinical trials are research studies designed to answer scientific questions and discover better ways to prevent, diagnose or treat various diseases and conditions, including cancer. A clinical trial is one of the final stages of a long and careful cancer research process. Scientists begin by developing and testing new ideas in a laboratory. If an approach seems promising, the next step may be testing a treatment in animals to learn how it affects cancer in a living being, and whether it has harmful effects.

Treatments that work well in the lab or in animals, however, may not always work well in people. When the potential treatment is deemed safe enough to explore its effects on humans, it proceeds to be studied in a clinical trial. In the context of cancer, these trials are performed with cancer patients to learn whether promising treatments are safe and effective.

Clinical trials are divided into four phases:

  • Phase 1 – These studies are to find the same does of a drug, to decide how a potential new treatment should be given, or to see how a potential new treatment affect the human body and fights cancer.
  • Phase 2 – These studies are to determine if a potential new treatment has an effect on a certain cancer and to see how it affects the human body and fights cancer.
  • Phase 3 –Phase III studies compare a new potential treatment with the current standard treatment.
  • Phase 4 – Phase 4 studies study the long-term safety and effectiveness of new treatments.  They take place after the treatment has been approved by the US Food and Drug Administration (FDA) and is on the market.

The most successful cancer treatments today are based on what we have learned from clinical trials. As a result, people with cancer are living longer, with a better quality of life. Participating in clinical trials at the University of Illinois Cancer Center may not only benefit you, but it could also help future patients through the development of newer, safer treatments.

For more information about clinical trials and why it is important to participate in clinical trials, please go to the brochure below:



 For more information about cancer clinical trials, please see the following resources: National Cancer Institute (NCI), Clinical Trials Information for Patients and CaregiversThe American Cancer Society, Clinical TrialsCancer Support Community, Cancer Clinical clinical trials database.

Below is a listing of UI Cancer Center clinical studies currently enrolling participants.  Click on the dropdown menu below to filter the list by the site of your disease.  If you are interested in participating in a trial listed, please email or call 312-355-5112.

For more information on the study, click on the ID, if available.

For a list of clinical trials nationwide, please see

Study Title Researcher Adult/Children Sponsor Disease Site ID
Prostate Cancer Detection Using a Quantitative Screening MRI ProtocolAbern, Michael RyanAdultsProstate
A031501: Phase III Randomized Adjuvant Study Of MK-3475 (Pembrolizumab) In Muscle Invasive And Locally Advanced Urothelial Carcinoma (Ambassador) Versus ObservationAbern, Michael RyanAdultsAllianceUrinary Bladder NCT03244384
BTCRC-BRE18-337: Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in_x000D_ Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersDanciu, Oana, CAdultsBig Ten Cancer Research ConsortiumBreast – Female; Breast – Male NCT03911973
NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast CancerDanciu, Oana, CAdultsNRG Oncology NCT03199885
EAY131 Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHCDanciu, Oana, CAdultsECOG-ACRIN NCT02465060
EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing ResultDanciu, Oana, CAdultsECOG-ACRIN NCT02465060
EAY131 Z1E: LOXO-101 in Patients with Tumors with NTRK FusionsDanciu, Oana, CAdultsECOG-ACRIN NCT02465060
S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast CancerDanciu, Oana, CAdultsSouthwest Oncology GroupBreast NCT03598257
C3441020: A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center_x000D_ Study of Talazoparib For Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients with Early Triple-Negative Breast CancerDanciu, Oana, CAdultsPfizer IncBreast NCT03499353
EAY131: Molecular Analysis for Therapy Choice (MATCH)Danciu, Oana, CAdultsEastern Cooperative Oncology GroupBrain and Nervous System; Breast – Female; Breast – Male; Colon; Esophagus; Hodgkin’s Lymphoma; Ill-Defined Sites; Kidney; Larynx; Leukemia, not otherwise specified; Liver; Lung; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin’s Lymphoma; Other Digestive Organ; Other Endocrine System; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Urinary; Pancreas; Prostate; Rectum; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder NCT02465060
A011401: Randomized Phase III Trial Evaluating The Role Of Weight Loss In Adjuvant Treatment Of Overweight And Obese Women With Early Breast CancerDanciu, Oana, CAdultsAllianceBreast – Female NCT02750826
S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With Greater than or Equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant ChemotherapyDanciu, Oana, CAdultsSouthwest Oncology GroupBreast NCT02954874
A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC TrialDanciu, Oana, CAdultsAllianceBreast NCT02927249
NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast CancerDanciu, Oana, CAdultsNRG OncologyBreast NCT02488967
STM-03: Phase I Study of PAC-1 in the Treatment of Advanced Hematologic Malignancy or Solid TumorsDanciu, Oana, CAdultsVanquish Oncology, Inc.Anus; Bones and Joints; Brain and Nervous System; Breast – Female; Breast – Male; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin’s Lymphoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Non-Hodgkin’s Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder NCT02355535
NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus AtezolizumabFeldman, LawrenceAdultsNRG OncologyLung NCT03811002
NRG-LU003: A Biomarker-Driven Protocol for Previously Treated ALK-Positive NSCLC Patients: The NCI-NRG ALK Master ProtocolFeldman, LawrenceAdultsNRG OncologyLung NCT03737994
NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III TrialFeldman, LawrenceAdultsNRG OncologyLung NCT03137771
BTCRC LUN17-139: A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-nave Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research ConsortiumFeldman, LawrenceAdultsBig Ten Cancer Research ConsortiumLung NCT03713944
E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinFeldman, LawrenceAdultsECOG-ACRINLung NCT02201992
A081105: Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)Feldman, LawrenceAdultsAllianceLung NCT02193282
EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersFeldman, LawrenceAdultsECOG-ACRINLung NCT02595944
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)Feldman, LawrenceAdultsAllianceLung NCT02194738
BTCRC-LUN17-127: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127Feldman, LawrenceAdultsBig Ten Cancer Research ConsortiumLung NCT03575793
AFT-28: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)Feldman, LawrenceAdultsAlliance Foundation Trials (AFT)Breast – Female; Colon; Kidney; Larynx; Liver; Lung; Other Digestive Organ; Other Respiratory and Intrathoracic Organs; Pancreas; Prostate; Soft Tissue; Stomach NCT02744092
ARRAY-818-103: Phase I Drug-Drug Interaction (DDI) Study with Encorafenib and Binimetinib in Patients with BRAF V600E-Mutant Melanoma or Other Advanced Solid Tumors with the BRAF V600E-MutationFeldman, LawrenceAdultsArray Biopharma Inc.Anus; Breast; Colon; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Other Digestive Organ; Other Female Genital; Other Male Genital; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach NCT03864042
A221504-Randomized, Double Blind Placebo Controlled Pilot Study of an Oral Selective Peripheral Opioid Receptor Antagonist in Advanced NSCLC (Adenocarcinoma)Feldman, LawrenceAdultsAllianceLung NCT03087708
RiMO-CL17-001: Phase I Dose-Escalating Study of RiMO-301 with Radiation in Advanced TumorsFeldman, LawrenceAdultsUniversity of ChicagoAnus; Bones and Joints; Brain and Nervous System; Breast – Female; Breast – Male; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin’s Lymphoma; Ill-Defined Sites; Kaposi’s sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Non-Hodgkin’s Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Urinary Bladder NCT03444714
IDR-OM-02: A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and NeckFeldman, LawrenceAdultsSoligenix, IncLip, Oral Cavity and Pharynx NCT03237325
BTCRC-LUN16-081: Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)Feldman, LawrenceAdultsBig Ten Cancer Research ConsortiumLung NCT03285321
BTCRC-LUN15-017: Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Non-small Cell Lung Cancer Who Progressed after First Line ChemotherapyFeldman, LawrenceAdultsBig Ten Cancer Research ConsortiumLung NCT03003468
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaGalvin, John, PatrickAdultsIncyte CorporationNon-Hodgkin’s Lymphoma NCT03688152
BGB-3111-212: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular LymphomaGalvin, John, PatrickAdultsBeiGene LtdNon-Hodgkin’s Lymphoma NCT03332017
Building a Cancer Survivor Support NetworkHamlish, TamaraAdultsUniversity of Illinois at Chicago (UIC)Anus; Breast – Female; Colon; Corpus Uteri; Lung; Other Female Genital; Other Male Genital; Ovary; Prostate; Rectum; Urinary Bladder
BRE-01: Phase 2 Trial Of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed By Doxorubicin And Cyclophosphamide In Triple Negative Breast CancerHoskins, KentAdultsUniversity of Illinois at Chicago (UIC)Breast – Female NCT04083963
MA-39: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast CancerHoskins, KentAdultsCCTGBreast NCT03488693
A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502Hoskins, KentAdultsAllianceBreast NCT03609021
A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast ReconstructionHoskins, KentAdultsAllianceBreast – Female NCT03414970
S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase IIIHoskins, KentAdultsSouthwest Oncology GroupBreast NCT03418961
PATINA (AFT-38): A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast CancerHoskins, KentAdultsAlliance Foundation Trials (AFT)Breast NCT02947685
Creating a Culturally-Tailored Intervention to Improve Uptake of Genetic Counseling Among Underserved African American Women with Increased Breast Cancer RiskHoskins, KentAdultsNational Cancer InstituteBreast – Female NCT04082117
A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Clinical Trial of Recombinant Human Deoxyribonuclease (Rhdnase) Eye Drops in Patients With Ocular Graft-Vs.-Host DiseaseJain, SandeepAdultsNational Eye Institute; National Institute of Health NCT02702518
A Prospective Study to Identify Bio-Markers that Predict Onset and Progression of Ocular Graft-Vs.-Host Disease in Patients who receive Allogeneic Hematopoietic Stem Cell TransplantJain, SandeepAdultsUniversity of Illinois at Chicago (UIC)
A041701: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyKhan, IrumAdultsAllianceMyeloid and Monocytic Leukemia NCT03701308
KRT-232-102: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b_x000D_ Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232_x000D_ Compared to Ruxolitinib in Patients with Phlebotomy-Dependent_x000D_ Polycythemia VeraKhan, IrumAdultsKartos Therapeutics, IncOther Hematopoietic NCT03669965
KRT-232-101: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed a JAK InhibitorKhan, IrumAdultsKartos Therapeutics, IncOther Hematopoietic NCT03662126
OncoNova 04-30: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome After Failure of a Hypomethylating AgentKhan, IrumAdultsOnconovaOther Hematopoietic NCT02562443
Behavioral and Neurophysiological Assessment of Hot and Cold Memory and Executive Function in Treated Breast Cancer PatientsKlumpp, HeideAdultsUniversity of Illinois at Chicago (UIC)
Effects of Stellate Ganglion Block on Vasomotor Symptoms in Women Receiving Anti-Estrogen Therapy for Breast CancerMaki, PaulineAdultsNorthwestern UniversityBreast – Female NCT02513329
Assessing and Modeling Network-level Consequences of Patient NavigationMolina, YamileAdultsNational Cancer InstituteBreast – Female
S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate CancerMoreira, DanielAdultsSouthwest Oncology GroupProstate NCT03678025
NRG-BN003: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II MeningiomaNicholas, Martin (Kelly)AdultsNRG OncologyBrain and Nervous System NCT03180268
S1803: Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)Patel, Pritesh, RAdultsSouthwest Oncology GroupMultiple Myeloma NCT04071457
A061202: A Phase I/II Study Of Pomalidomide, Dexamethasone And Ixazomib Vs. Pomalidomide And Dexamethasone For Patients With Multiple Myeloma Refractory To Lenalidomide And Proteasome Inhibitor-Based TherapyPatel, Pritesh, RAdultsAllianceMultiple Myeloma NCT02004275
A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell SubtypePatel, Pritesh, RAdultsAllianceNon-Hodgkin’s Lymphoma NCT02443077
ProSTAR 1205-201: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate CancerPeace, David, JAdultsConstellation Pharma, IncProstate NCT03480646
BTCRC-HEM15-027: Phase I Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaPeace, David, JAdultsBig Ten Cancer Research ConsortiumHodgkin’s Lymphoma NCT03681561
BTCRC-HEM15-028: Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)Peace, David, JAdultsBig Ten Cancer Research ConsortiumNon-Hodgkin’s Lymphoma NCT03547700
NRG-GU006: A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate CancerPeace, David, JAdultsNRG OncologyProstate NCT03371719
HCRN GU16-260: Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaPeace, David, JAdultsBig Ten Cancer Research ConsortiumKidney NCT03117309
BTCRC-GU16-043: Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney CancerPeace, David, JAdultsBig Ten Cancer Research ConsortiumKidney NCT03308396
CA209901 A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial CancerPeace, David, JAdultsBristol-Myers SquibbUrinary Bladder NCT03036098
ARO-021: Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid LeukemiaQuigley, John (Sean)AdultsAROG Pharmaceuticals, IncMyeloid and Monocytic Leukemia NCT03258931
A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) With Chronic Lymphocytic Leukemia (CLL)Quigley, John (Sean)AdultsAllianceLymphoid Leukemia NCT03737981
Phase Ib Study of the Safety and Efficacy Of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid LeukemiaQuigley, John (Sean)AdultsBig Ten Cancer Research ConsortiumMyeloid and Monocytic Leukemia; Other Hematopoietic NCT04070768
A041501: A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39) With Newly Diagnosed Precursor B-Cell ALLQuigley, John (Sean)AdultsAllianceLymphoid Leukemia NCT03150693
E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in AdultsQuigley, John (Sean)AdultsEastern Cooperative Oncology GroupLymphoid Leukemia NCT02003222
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH 3)Rondelli, DamianoAdultsIncyte CorporationOther Hematopoietic NCT03112603
BMT-05: A Phase II Study of Intensity Modulated Total Marrow Irradiation (TMI) in Addition to Fludarabine/ Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesRondelli, DamianoAdultsUniversity of Illinois at Chicago (UIC)Leukemia, not otherwise specified; Leukemia, other; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin’s Lymphoma; Other Hematopoietic NCT03121014
AGCT1532: Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursSchmidt, Mary LouBothChildren’s Oncology GroupOther Male Genital; Ovary NCT02582697
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell TumorsSchmidt, Mary LouBothChildren’s Oncology GroupOther Female Genital; Other Male Genital; Ovary NCT03067181
ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E MutationsSchmidt, Mary LouBothChildren’s Oncology GroupBrain and Nervous System NCT03581292
APEC1621-SC, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolSchmidt, Mary LouBothChildren’s Oncology GroupBones and Joints; Brain and Nervous System; Cervix; Kidney; Leukemia, not otherwise specified; Leukemia, other; Liver; Lymphoid Leukemia; Non-Hodgkin’s Lymphoma; Other Female Genital; Other Male Genital; Soft Tissue NCT03155620
ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)Schmidt, Mary LouBothChildren’s Oncology GroupSoft Tissue NCT03126916
AALL1631, International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy BackbonesSchmidt, Mary LouBothChildren’s Oncology GroupLymphoid Leukemia
ALTE16C1, Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma_x000D_Schmidt, Mary LouAdultsChildren’s Oncology GroupBones and Joints NCT03206450
ALTE1621, Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer _x000D_ Survivors at Risk for Heart Failure (PREVENT-HF):A Phase 2b Randomized Placebo Controlled (Carvedilol) TrialSchmidt, Mary LouBothChildren’s Oncology GroupOther Respiratory and Intrathoracic Organs NCT02717507
ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)Schmidt, Mary LouBothChildren’s Oncology GroupBones and Joints; Soft Tissue NCT02567435
ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma PatientsSchmidt, Mary LouBothChildren’s Oncology GroupBrain and Nervous System; Eye and Orbit NCT02724579
AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene RearrangementSchmidt, Mary LouChildrenChildren’s Oncology GroupLeukemia, other; Lymphoid Leukemia NCT02828358
AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down SyndromeSchmidt, Mary LouChildrenChildren’s Oncology GroupMyeloid and Monocytic Leukemia NCT02521493
AALL1331:Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Schmidt, Mary LouBothChildren’s Oncology GroupLymphoid Leukemia NCT02101853
ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk NeuroblastomaSchmidt, Mary LouChildrenChildren’s Oncology GroupSoft Tissue NCT02176967
ALTE07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with CancerSchmidt, Mary LouBothChildren’s Oncology GroupBrain and Nervous System NCT00772200
Investigational Oocyte Cryopreservation for Medical and Non Medical IndicationsScoccia, HumbertoAdultsUniversity of Illinois at Chicago (UIC)Ovary
Exploring The Use Of Electronic Medication Monitors To Support Adherence In Cancer PatientsSharp, LisaAdultsUniversity of Illinois at Chicago (UIC)Hodgkin’s Lymphoma; Leukemia, not otherwise specified; Leukemia, other; Lymphoid Leukemia; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin’s Lymphoma; Other Hematopoietic
A031702: Phase II Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary TumorsShergill, ArdamanAdultsAllianceKidney; Other Male Genital; Prostate; Urinary Bladder NCT03866382
A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene AlterationsShergill, ArdamanAdultsAllianceUrinary Bladder NCT03609216
A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell TumorsShergill, ArdamanAdultsAllianceOther Female Genital; Other Male Genital; Ovary NCT02375204
NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to CisplatinShergill, ArdamanAdultsNRG OncologyEsophagus; Larynx; Lip, Oral Cavity and Pharynx NCT03258554
EA3132: Phase II randomized trial of radiotherapy with or without cisplatin for surgically resected squamous cell carcinoma of head and neck (SCCHN) with TP53 sequencingShergill, ArdamanAdultsEastern Cooperative Oncology GroupLip, Oral Cavity and Pharynx NCT02734537
Diet Modulation of Bacterial Sulfur & Bile Acid Metabolism and Colon Cancer Risk_x000D_Tussing-Humphreys, LisaAdultsNational Cancer InstituteColon NCT03550885
S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract CancersVenepalli, Neeta, KAdultsSouthwest Oncology GroupLiver; Other Digestive Organ NCT03768414
EA 2165: Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal CancerVenepalli, Neeta, KAdultsEastern Cooperative Oncology GroupAnus NCT03233711
NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal CancerVenepalli, Neeta, KAdultsNRG OncologyColon; Rectum NCT02997228
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)Venepalli, Neeta, KAdultsSouthwest Oncology GroupColon; Rectum NCT01349881
BTCRC-GI15-015: A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction AdenocarcinomaVenepalli, Neeta, KAdultsBig Ten Cancer Research ConsortiumEsophagus; Stomach NCT03283761
RTOG 1112: Randomized Phase III Study of Sorafenib Versus Sterotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular CarcinomaVenepalli, Neeta, KAdultsRadiation Therapy Oncology GroupLiver NCT01730937
Evaluating the Use of an Informational Head and Neck Cancer Website for Patient and Family Education_x000D_Wenig, BarryAdultsUniversity of Illinois at Chicago (UIC)Lip, Oral Cavity and Pharynx